Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: study design, rationale and objectives.
Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, de Man FH, Louwerenburg JW, Saïd SA, Linssen GC, Kleijne MA, van der Palen J, Huisman J, Verhorst PM, von Birgelen C. Basalus MW, et al. Among authors: van houwelingen kg, van der palen j. Neth Heart J. 2010 Aug;18(7-8):360-4. doi: 10.1007/BF03091792. Neth Heart J. 2010. PMID: 20730003 Free PMC article.
Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study.
Kok MM, von Birgelen C, Lam MK, Löwik MM, van Houwelingen KG, Stoel MG, Louwerenburg JH, de Man FH, Hartmann M, Doggen CJ, van Til JA, IJzerman MJ. Kok MM, et al. Among authors: van til ja, van houwelingen kg. EuroIntervention. 2016 Apr 20;11(13):1487-94. doi: 10.4244/EIJY15M10_06. EuroIntervention. 2016. PMID: 26465376 Free article.
Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, Gin RMTJ, Somi S, van Houwelingen KG, Stoel MG, de Man FHAF, Louwerenburg JHW, Hartmann M, Zocca P, Linssen GCM, van der Palen J, Doggen CJM, Löwik MM. von Birgelen C, et al. Among authors: van houwelingen kg, van der heijden lc, van der palen j. Lancet. 2016 Nov 26;388(10060):2607-2617. doi: 10.1016/S0140-6736(16)31920-1. Epub 2016 Oct 30. Lancet. 2016. PMID: 27806902 Clinical Trial.
Diagnostic and therapeutic approach of congenital solitary coronary artery fistulas in adults: Dutch case series and review of literature.
Said SA, Nijhuis RL, Op den Akker JW, Kimman GP, Van Houwelingen KG, Gerrits D, Huisman AB, Slart RH, Nicastia DM, Koomen EM, Tans AC, Al-Windy NY, Sonker U, Slagboom T, Pronk AC. Said SA, et al. Among authors: van houwelingen kg. Neth Heart J. 2011 Apr;19(4):183-91. doi: 10.1007/s12471-011-0088-2. Neth Heart J. 2011. PMID: 22020997 Free PMC article.
Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals.
Nijenhuis VJ, Stella PR, Baan J, Brueren BR, de Jaegere PP, den Heijer P, Hofma SH, Kievit P, Slagboom T, van den Heuvel AF, van der Kley F, van Garsse L, van Houwelingen KG, Van't Hof AW, Ten Berg JM. Nijenhuis VJ, et al. Among authors: van den heuvel af, van der kley f, van garsse l, van t hof aw, van houwelingen kg. Neth Heart J. 2014 Feb;22(2):64-9. doi: 10.1007/s12471-013-0496-6. Neth Heart J. 2014. PMID: 24287807 Free PMC article.
High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial.
Hermanides RS, Heestermans AA, Ten Berg JM, Gosselink AT, Ottervanger JP, van Houwelingen KG, Kolkman JJ, Stella PR, Dill T, Hamm C, van 't Hof AW. Hermanides RS, et al. Among authors: van t hof aw, van houwelingen kg. Heart. 2011 Jan;97(2):106-11. doi: 10.1136/hrt.2010.194951. Epub 2010 Oct 20. Heart. 2011. PMID: 20962338 Clinical Trial.
Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 Years.
Ploumen EH, Wolcherink MJO, Buiten RA, Pinxterhuis TH, Doggen CJM, Schotborgh CE, Danse PW, Scholte M, van Houwelingen KG, Zocca P, Pouwels XGLV, von Birgelen C. Ploumen EH, et al. Among authors: van houwelingen kg. Pharmacoecon Open. 2024 Oct 29. doi: 10.1007/s41669-024-00539-x. Online ahead of print. Pharmacoecon Open. 2024. PMID: 39472363 Free article.
Ethnic minorities treated with new-generation drug-eluting coronary stents in two European randomised clinical trials.
Ploumen EH, Semedo E, Doggen CJM, Schotborgh CE, Anthonio RL, Danse PW, Benit E, Aminian A, Stoel MG, Hartmann M, van Houwelingen KG, Scholte M, Roguin A, Linssen GCM, Zocca P, von Birgelen C. Ploumen EH, et al. Among authors: van houwelingen kg. Neth Heart J. 2024 Jun;32(6):254-261. doi: 10.1007/s12471-024-01873-9. Epub 2024 May 22. Neth Heart J. 2024. PMID: 38776038 Free PMC article.
Invasiveness of previous treatment for peripheral arterial disease and risk of adverse cardiac events after coronary stenting.
Pinxterhuis TH, von Birgelen C, Geelkerken RH, Doggen CJM, Menting TP, van Houwelingen KG, Linssen GCM, Ploumen EH. Pinxterhuis TH, et al. Among authors: van houwelingen kg. Cardiovasc Interv Ther. 2024 Apr;39(2):173-182. doi: 10.1007/s12928-024-00986-7. Epub 2024 Feb 14. Cardiovasc Interv Ther. 2024. PMID: 38353865 Free PMC article.
64 results